CSIMarket
 
Vertex Pharmaceuticals Inc  (VRTX)
Other Ticker:  
 
 
Price: $407.6900 $-1.08 -0.264%
Day's High: $411.64 Week Perf: -1.64 %
Day's Low: $ 406.97 30 Day Perf: -2.44 %
Volume (M): 1,906 52 Wk High: $ 448.40
Volume (M$): $ 776,935 52 Wk Avg: $365.27
Open: $410.10 52 Wk Low: $296.09



 Market Capitalization (Millions $) 106,240
 Shares Outstanding (Millions) 261
 Employees 3,900
 Revenues (TTM) (Millions $) 9,869
 Net Income (TTM) (Millions $) 3,620
 Cash Flow (TTM) (Millions $) -140
 Capital Exp. (TTM) (Millions $) 258

Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Inc. is a biotechnology company that focuses on discovering, developing, and commercializing innovative medicines for serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Inc. has become a leading player in the field of cystic fibrosis, a genetic disease that affects the lungs and other organs. The company's first drug, Kalydeco, was approved in 2012 and was the first drug to treat the underlying cause of cystic fibrosis in patients with a specific genetic mutation. Since then, Vertex Pharmaceuticals Inc. has developed other drugs for cystic fibrosis, including Orkambi and Symdeko, which have greatly improved the lives of patients.

Aside from its work in cystic fibrosis, Vertex Pharmaceuticals Inc. is also exploring other therapeutic areas, including sickle cell disease, beta thalassemia, and pain management. The company's research and development efforts are focused on small molecules and gene therapies, with the goal of developing precision medicines that target the underlying cause of diseases.

In addition to its drug development efforts, Vertex Pharmaceuticals Inc. is committed to corporate social responsibility. The company has a strong commitment to environmental sustainability and works to reduce its carbon footprint through energy conservation, recycling, and sustainable building practices. The company is also committed to supporting patient advocacy groups and has established programs to help patients access its medications.

Overall, Vertex Pharmaceuticals Inc. is a company that is dedicated to developing innovative medicines for serious diseases, while also maintaining a strong commitment to corporate social responsibility. With its cutting-edge research, talented team of scientists and clinicians, and commitment to patients and the community, Vertex Pharmaceuticals Inc. is poised to continue making a significant impact in the field of biotechnology.


   Company Address: 50 Northern Avenue Boston 2210 MA
   Company Phone Number: 341-6100   Stock Exchange / Ticker: NASDAQ VRTX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc Achieves Remarkable Top-line Growth, Surpassing Expectations in the Latest Fiscal Period

Vertex Pharmaceuticals Inc has experienced a slight drop in its stock price, specifically by -0.2% over the past 30 days. However, when looking at the bigger picture, the share price has increased by 9.63% in the past 90 days. This indicates a positive trend in the company's stock performance. Additionally, the stock is only 5.7% short of its 52-week high, suggesting that there is potential for further growth.
Analyzing the financial results, it is evident that Vertex Pharmaceuticals Inc has achieved encouraging revenue growth during the fourth quarter of the 2023 earnings season. Revenue increased by 9.337% to $2.52 billion, compared to $2.30 billion in the prior year quarter. This performance surpasses the overall sector peers' growth of 3.00% during the same period.

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc. Soars Ahead with Impressive Financial Results in Q3 2023: Revenue and EPS on the Rise

Vertex Pharmaceuticals Inc, a leading pharmaceutical company, has reported a solid third quarter of 2023 with impressive financial results. The company's revenue saw a modest increase of 6.392% to $2.48 billion compared to $2.33 billion in the previous year. Additionally, the company recorded a 10.58% rise in income to $3.97 per share, up from $3.59 in the prior year reporting period.
One notable highlight is that Vertex Pharmaceuticals Inc has clearly outperformed its industry peers in terms of revenue growth. While the rest of the Major Pharmaceutical Preparations industry only showed a 1.86% increase in revenue during the same time period, Vertex Pharmaceuticals Inc managed to stand out. However, it's worth mentioning that there was a slight decrease of 0.389% in revenue from the previous period of $2.49 billion.

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Shatters Expectations in Second Quarter Earnings, Skyrocketing Above Industry Average for April-June 2023 Period!

Vertex Pharmaceuticals Inc Reports Strong Q2 2023 Results, Poised for Future Success
August 4, 2023
Vertex Pharmaceuticals Inc, a major player in the pharmaceutical industry, has announced its financial results for the second quarter of 2023. The company achieved remarkable revenue of $2.49 billion, representing a year-on-year growth of 13.523%. Additionally, earnings per share (EPS) for the quarter stood at $3.52, marking a growth of 12.46%.
These outstanding results indicate Vertex Pharmaceuticals Inc's continuous progress and success in the industry. Compared to its competitors in the Major Pharmaceutical Preparations sector, the company experienced significantly higher business growth. While the sector averaged a 3.96% growth in the same period, Vertex outperformed with an impressive 13.523%.

Vertex Pharmaceuticals Inc

Earnings deteriorated In spite of Strong revenue by in the fiscal period ending March 31 2023

Vertex Pharmaceuticals Inc's first quarter of 2023 earnings report shows a return on average invested assets (ROI) of 22.3%, which is slightly lower than the company's average ROI of 23.36%. This decrease in ROI can be attributed to a decline in net income during the quarter.
Despite the decrease in ROI, Vertex Pharmaceuticals performed well within the healthcare sector, outperforming 33 other companies. However, when compared to the fourth quarter of 2022, the company's total ROI ranking has deteriorated from 77 to 309.






 

Vertex Pharmaceuticals Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Vertex Pharmaceuticals Inc does not provide revenue guidance.

Earnings Outlook
Vertex Pharmaceuticals Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com